SEARCH

MEDIA PACK

NEWS

Current Edition

clostridium difficile

Discontinuation of Sanofi’s C. difficile Vaccine Program presents an opportunity for Pfizer and Valneva, observes GlobalData

On December 1 2017, Sanofi Pasteur announced its intention to discontinue the Phase III development program for its Clostridium difficile vaccine. The vaccine was on …

20 December 2017 news clostridium difficile late-stage clinical

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

SEARCH

MENU

Current Edition

Discontinuation of Sanofi’s C. difficile Vaccine Program presents an opportunity for Pfizer and Valneva, observes GlobalData

Journal for Clinical Studies